Strata Critical Med (SRTA) stock
NASDAQ
As of the Nov 13, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- $490M
- As of Nov 13, 2026
- P/E
- -18.85x
- Trailing twelve months
- P/B
- 1.78x
- Latest reported equity
- P/S
- 2.07x
- Trailing twelve months
- ROE
- -9.4%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- $490M
- As of Nov 13, 2026
- P/E
- -18.85x
- Trailing twelve months
- P/B
- 1.78x
- Latest reported equity
- P/S
- 2.07x
- Trailing twelve months
- ROE
- -9.4%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
-18.85x
Net loss — not comparable
P/B
1.78x
P/S
2.07x
Earnings and dividend metrics▾
Earnings
EPS
-$0.29
Earnings per share
BPS
$3.10
Book value per share
ROE
-9.4%
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at $0.29 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $3.10 of net assets.
- ROE — shareholder equity shrank by 9.4% over a year.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 51.0% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $49M+51.0%
$75M
Jul–Sep '24
$49M
Jul–Sep '25
$74M
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Nov 3, 2026.
- Earnings per share decreased 112.9% from the same quarter a year earlier.
- Revenue increased 51.0% from the same quarter a year earlier.
- Operating income increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Net income decreased 114.0% from the same quarter a year earlier.
Filed Nov 3, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- LAUCK ANDREWDirector · Nov 5, 2026Open-market purchase2,000 shares · $10KAvg. price $4.999172,902 shares held after
- Wunsch Scott MCEO, Logistics · Oct 28, 2026Shares withheld for taxes44,996 shares · $214KAvg. price $4.76746,254 shares held after
- Wunsch Scott MCEO, Logistics · Oct 28, 2026Grant or award115,762 shares · $0Avg. price $0
Show 3 price lots
- 1,416 shares × $0$0
- 57,173 shares × $0$0
- 57,173 shares × $0$0
- Heyburn William A.Co-CEO and CFO · Sep 24, 2026Shares withheld for taxes98,356 shares · $518KAvg. price $5.271,757,850 shares held after
- Tomkiel Melissa M.Co-CEO and General Counsel · Sep 24, 2026Shares withheld for taxes90,797 shares · $479KAvg. price $5.272,153,678 shares held after
- Heyburn William A.Co-CEO and CFO · Sep 24, 2026Grant or award177,858 shares · $0Avg. price $01,856,206 shares held after
- Tomkiel Melissa M.Co-CEO and General Counsel · Sep 24, 2026Grant or award177,858 shares · $0Avg. price $02,244,475 shares held after
- Heyburn William A.Co-CEO and CFO · Sep 8, 2026Shares withheld for taxes31,671 shares · $168KAvg. price $5.311,678,348 shares held after
- Tomkiel Melissa M.Co-CEO and General Counsel · Sep 8, 2026Shares withheld for taxes29,730 shares · $158KAvg. price $5.312,066,617 shares held after
- Wunsch Scott MCEO, Logistics · Sep 8, 2026Shares withheld for taxes5,711 shares · $30KAvg. price $5.31663,043 shares held after
- Verdetto Louis R.CEO, Clinical Services · Sep 8, 2026Shares withheld for taxes5,697 shares · $30KAvg. price $5.311,128,096 shares held after
- Cohen AmirChief Accounting Officer · Sep 8, 2026Shares withheld for taxes4,645 shares · $25KAvg. price $5.31177,154 shares held after
- Love ReginaldDirector · Aug 10, 2026Open-market sale5,091 shares · $29KAvg. price $5.75146,481 shares held after
- Tomkiel Melissa M.Co-CEO and General Counsel · Jul 31, 2026Shares withheld for taxes212,309 shares · $1.1MAvg. price $5.092,096,347 shares held after
- Heyburn William A.Co-CEO and CFO · Jul 31, 2026Shares withheld for taxes199,209 shares · $1.0MAvg. price $5.091,710,019 shares held after
- Cohen AmirChief Accounting Officer · Jul 31, 2026Shares withheld for taxes34,015 shares · $173KAvg. price $5.09181,799 shares held after
- Wunsch Scott MCEO, Logistics · Jul 31, 2026Shares withheld for taxes13,992 shares · $71KAvg. price $5.09668,754 shares held after
- Tomkiel Melissa M.Co-CEO and General Counsel · Jul 30, 2026Grant or award415,882 shares · $0Avg. price $0
Show 2 price lots
- 208,929 shares × $0$0
- 206,953 shares × $0$0
- Wunsch Scott MCEO, Logistics · Jul 30, 2026Grant or award69,617 shares · $0Avg. price $0
Show 3 price lots
- 57,172 shares × $0$0
- 9,787 shares × $0$0
- 2,658 shares × $0$0
- WIESENTHAL ROBERT SDirector · Jul 30, 2026Grant or award50,234 shares · $0Avg. price $05,325,896 shares held after
- Heyburn William A.Co-CEO and CFO · Jul 30, 2026Grant or award360,231 shares · $0Avg. price $0
Show 2 price lots
- 181,071 shares × $0$0
- 179,160 shares × $0$0
- Cook William L. IIIDirector · Jul 30, 2026Grant or award44,438 shares · $0Avg. price $097,671 shares held after
- Cohen AmirChief Accounting Officer · Jul 30, 2026Grant or award69,206 shares · $0Avg. price $0
Show 2 price lots
- 27,420 shares × $0$0
- 41,786 shares × $0$0
- LAUCK ANDREWDirector · Jul 30, 2026Grant or award35,260 shares · $0Avg. price $0170,902 shares held after
- Love ReginaldDirector · Jul 30, 2026Grant or award37,675 shares · $0Avg. price $0151,572 shares held after
- PHILIP EDWARD MDirector · Jul 30, 2026Grant or award30,913 shares · $0Avg. price $0265,078 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Strata Critical Med (SRTA) stock information
NASDAQ
Strata Critical Med (SRTA) is listed on NASDAQ. Its market capitalization is about $490M. On trailing-twelve-month earnings the P/E ratio is -18.85, and the P/B ratio is 1.78. Return on equity is -9.4%. These figures are computed in-house from official filings and are reference information only.
Strata Critical Med — frequently asked questions
- What is the P/E ratio of Strata Critical Med (SRTA)?
- On a trailing-twelve-month basis, SRTA trades at a P/E ratio of -18.85. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Strata Critical Med?
- SRTA has a market capitalization of about $490M. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.